Literature DB >> 11728994

A case of familial Mediterranean fever with amyloidosis as the first manifestation.

S Kutlay1, E Yilmaz, E S Koytak, O Tulunay O, K Keven, M Ozcan, S Ertürk.   

Abstract

We describe a 22-year-old Turkish woman with nephrotic syndrome who had a history of acute myelocytic leukemia. After careful clinical evaluation, the patient underwent a renal biopsy. Light microscopic examination showed deposition of Congo-positive material both in the mesangium and around the small vessels. By histochemical analyses, the deposited material was proved to be amyloid A (AA). Because the patient's history did not reveal any event that might explain the development of secondary amyloidosis, she was screened for mutations causing familial Mediterranean fever (FMF) and was found to be homozygous for the M694V mutation by denaturing gradient gel electrophoresis. We recommend that FMF-Phenotype II and the development of amyloid nephropathy, before or without other symptoms of FMF, should be kept in mind in the face of unexplained proteinuria/amyloidosis, especially in high-risk ethnic groups.

Entities:  

Mesh:

Year:  2001        PMID: 11728994     DOI: 10.1053/ajkd.2001.29290

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

Review 1.  Familial Mediterranean fever.

Authors:  Fatos Onen
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

2.  Prevalence and significance of the MEFV gene mutations in childhood Henoch-Schönlein purpura without FMF symptoms.

Authors:  Cagla Serpil Dogan; Sema Akman; Mustafa Koyun; Turker Bilgen; Elif Comak; Arife Uslu Gokceoglu
Journal:  Rheumatol Int       Date:  2012-03-27       Impact factor: 2.631

3.  Living kidney transplantation between brothers with unrecognized renal amyloidosis as the first manifestation of familial Mediterranean fever: a case report.

Authors:  Ramón Peces; Sara Afonso; Carlos Peces; Julián Nevado; Rafael Selgas
Journal:  BMC Med Genet       Date:  2017-08-31       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.